Literature DB >> 21152111

Advances in the Pharmacological Treatment of Atrial Fibrillation.

Alexander Burashnikov1, Charles Antzelevitch.   

Abstract

Entities:  

Year:  2010        PMID： 21152111      PMCID： PMC2997698     

Source DB:  PubMed          Journal:  Curr Med Lit Cardiol        ISSN： 1354-0122


× No keyword cloud information.
  34 in total

Review 1.  Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling).

Authors:  Andreas Goette; Alicja Bukowska; Uwe Lendeckel
Journal:  Curr Opin Pharmacol       Date:  2007-02-02       Impact factor: 5.547

Review 2.  Potassium channels in atrial fibrillation: targets for atrial and pathology-specific therapy?

Authors:  Ursula Ravens
Journal:  Heart Rhythm       Date:  2007-11-07       Impact factor: 6.343

3.  Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation.

Authors:  D R Van Wagoner; A L Pond; P M McCarthy; J S Trimmer; J M Nerbonne
Journal:  Circ Res       Date:  1997-06       Impact factor: 17.367

4.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

Review 5.  Innovative approaches to anti-arrhythmic drug therapy.

Authors:  Stanley Nattel; Leif Carlsson
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

6.  Increased mortality after dronedarone therapy for severe heart failure.

Authors:  Lars Køber; Christian Torp-Pedersen; John J V McMurray; Ole Gøtzsche; Samuel Lévy; Harry Crijns; Jan Amlie; Jan Carlsen
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

7.  Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

Authors:  Paul Touboul; Josep Brugada; Alessandro Capucci; Harry J G M Crijns; Nils Edvardsson; Stefan H Hohnloser
Journal:  Eur Heart J       Date:  2003-08       Impact factor: 29.983

8.  Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol.

Authors:  W Spinelli; R W Parsons; T J Colatsky
Journal:  J Cardiovasc Pharmacol       Date:  1992-12       Impact factor: 3.105

9.  Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.

Authors:  Stuart J Connolly; Harry J G M Crijns; Christian Torp-Pedersen; Martin van Eickels; Christophe Gaudin; Richard L Page; Stefan H Hohnloser
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

10.  Valsartan for prevention of recurrent atrial fibrillation.

Authors:  Marcello Disertori; Roberto Latini; Simona Barlera; Maria Grazia Franzosi; Lidia Staszewsky; Aldo Pietro Maggioni; Donata Lucci; Giuseppe Di Pasquale; Gianni Tognoni
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.